1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,122.50
USD
-6.85
- -
1.06TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
80.68
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
28.23
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
11.58
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.24
Book Value per Share
15.84
15.47
15.11
15.2
13.86
11.73
5.76
8.81
10.02
11.19
12.13
15.75
28.01
33.62
Tangible Book Value per Share
11.92
9.68
4.99
5.22
3.11
8.25
-7.94
-5.64
-2.55
-0.53
-1.09
2.6
15.77
19.76
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
896
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
72,250
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
47.3
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,043
Net Income, GAAP
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
25,277
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
18.79
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
34.99
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
18,201
LT Debt
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
39,370
Total Equity
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
31,198
Return on Invested Capital (%)
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
41.09
Return on Capital (%)
21.27
10.43
10.21
11.15
-0.77
13.3
39.09
28.19
22.73
24.43
17.8
26.74
35.76
40.11
Return on Common Equity (%)
27.16
13.71
14.22
16.37
-1.3
24.27
94.66
88.81
62.08
61.86
48.65
84.57
105.31
110.39

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,633
1,635
4,000
LT Borrowings
40,874
40,868
39,370
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
896
895
894
Market Capitalization
684,603
963,523
823,663

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
62,071
55,629
54,835
Cash, Cash Equivalents & STI
9,914
7,268
5,282
Accounts Receivable, Net
16,107
17,760
18,429
Inventories
12,180
13,744
14,529
Total Current Liabilities
40,141
35,228
36,634
Payables & Accruals
31,327
22,761
22,576
ST Debt
1,633
1,635
4,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
David A. Ricks
Full Time Employees
47,000
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lilly Corporate Center Indianapolis IN United States of America 46285
IPO Date
Jun 1, 1972
CIK
0000059478
Website
lilly.com
Similar Companies
Sanofi (SNYNF)
PT Kalbe Farma Tbk. (KLBF.JK)
Dechra Pharmaceuticals PLC (DPHAY)
Santen Pharmaceutical Co., Ltd. (4536.T)
Kyowa Kirin Co., Ltd. (4151.T)
Daiichi Sankyo Company, Limited (DSNKY)
Business

Company News

MCPAPIChat

  • barrons.com

    Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

  • fool.com

    Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

  • fool.com

    Health Care ETFs: XLV Delivers Low Fees and Solid Returns

  • gurufocus.com

    Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

  • prnewswire.com

    Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

  • gurufocus.com

    Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

  • prnewswire.com

    Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

  • zacks.com

    Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

  • investors.com

    Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.

  • zacks.com

    Here's Why Eli Lilly (LLY) is a Strong Growth Stock

  • 247wallst.com

    Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy

  • benzinga.com

    American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades'

  • 247wallst.com

    Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

  • zacks.com

    Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

  • youtube.com

    MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer

  • 247wallst.com

    An AI Price War Is About to Break Out. You Won’t Believe Who Will Profit Most

  • etftrends.com

    Healthcare ETFs: From Broad Exposure to Big Breakthroughs

  • 247wallst.com

    I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

  • zacks.com

    Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care

  • reuters.com

    Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon